Pomalidomide Patent Expiration
Pomalidomide is used for treating multiple myeloma in patients who have already received other prior therapies. It was first introduced by Bristol Myers Squibb Co
Pomalidomide Patents
Given below is the list of patents protecting Pomalidomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Pomalyst |
US8828427 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Dec 21, 2031 | Bristol |
| Pomalyst | US8828427 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Jun 21, 2031 | Bristol |
| Pomalyst |
US10555939 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Nov 19, 2030 | Bristol |
| Pomalyst |
US9993467 (Pediatric) | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | Nov 19, 2030 | Bristol |
| Pomalyst | US10555939 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | May 19, 2030 | Bristol |
| Pomalyst | US9993467 | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione | May 19, 2030 | Bristol |
| Pomalyst |
US8198262 (Pediatric) | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | Dec 17, 2025 | Bristol |
| Pomalyst | US8198262 | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione | Jun 17, 2025 | Bristol |
| Pomalyst |
US8673939 (Pediatric) | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov 15, 2023
(Expired) | Bristol |
| Pomalyst |
US8735428 (Pediatric) | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov 15, 2023
(Expired) | Bristol |
| Pomalyst | US8673939 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May 15, 2023
(Expired) | Bristol |
| Pomalyst | US8735428 | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May 15, 2023
(Expired) | Bristol |
| Pomalyst | US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol |
| Pomalyst | US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol |
| Pomalyst | US6316471 | Isoindolines, method of use, and pharmaceutical compositions |
Aug 10, 2016
(Expired) | Bristol |
| Pomalyst | US8158653 | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
Aug 10, 2016
(Expired) | Bristol |
| Pomalyst | US5635517 | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Jul 24, 2016
(Expired) | Bristol |
| Pomalyst | US5653517 | Process and system for determination of friction/slip characteristics of road vehicle tires |
Jul 24, 2016
(Expired) | Bristol |
| Pomalyst | US6476052 | Isoindolines, method of use, and pharmaceutical compositions |
Jul 24, 2016
(Expired) | Bristol |
Pomalidomide's Family Patents
Explore Our Curated Drug Screens
Pomalidomide Generic API Manufacturers
Several generic applications have been filed for Pomalidomide. The first generic version for Pomalidomide was by Breckenridge Pharmaceutical Inc and was approved on Oct 30, 2020. And the latest generic version is by Hetero Labs Ltd Unit V and was approved on Sep 26, 2024.
Given below is the list of companies who have filed for Pomalidomide generic, along with the locations of their manufacturing plants worldwide.
1. APOTEX
Apotex Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |
| 1MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |
| 2MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |
| 3MG | capsule | Prescription | ORAL | AB | Jun 11, 2024 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
2. BRECKENRIDGE
Breckenridge Pharmaceutical Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Breckenridge.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 2MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 3MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 4MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
Manufacturing Plant Locations New
Breckenridge's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Breckenridge as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
3. EUGIA PHARMA
Eugia Pharma Specialities Ltd has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Eugia Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 4MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 3MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
| 2MG | capsule | Discontinued | ORAL | N/A | Oct 30, 2020 |
Manufacturing Plant Locations New
Eugia Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Eugia Pharma as present at those locations.
| Country | City | Firm Name | ||||||
|---|---|---|---|---|---|---|---|---|
| India |
| |||||||
4. HETERO LABS LTD V
Hetero Labs Ltd Unit V has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd V.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 2MG | capsule | Prescription | ORAL | AB | Sep 26, 2024 |
| 1MG | capsule | Prescription | ORAL | AB | Sep 26, 2024 |
| 4MG | capsule | Prescription | ORAL | AB | Sep 26, 2024 |
| 3MG | capsule | Prescription | ORAL | AB | Sep 26, 2024 |
5. MYLAN
Mylan Pharmaceuticals Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 4MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
| 1MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
| 2MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
| 3MG | capsule | Discontinued | ORAL | N/A | Jan 26, 2022 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
6. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Pomalidomide. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 1MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |
| 4MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |
| 2MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |
| 3MG | capsule | Discontinued | ORAL | N/A | May 4, 2022 |